Curated Information
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage PhosphoSitePlus® v6.5.9.3
Powered by Cell Signaling Technology
Home > Curated Information Page > PubMed Id: 21159648
Siddiqui-Jain A, et al. (2010) CX-4945, an orally bioavailable selective inhibitor of protein kinase CK2, inhibits prosurvival and angiogenic signaling and exhibits antitumor efficacy. Cancer Res 70, 10288-98 21159648
This page summarizes selected information from the record referenced above and curated into PhosphoSitePlus®, a comprehensive online resource for the study of protein post-translational modifications (NAR, 2015, 43:D512-20). To learn more about the scope of PhosphoSitePlus®, click here.
Information from this record has been curated, but not yet edited in PhosphoSitePlus® and may be incomplete.
Click on the protein name to open the protein page, and on the RSD number to open the site page.
Download

S129-p - Akt1 (human)
Modsite: sGsPsDNsGAEEMEV SwissProt Entrez-Gene
Orthologous residues
Akt1 (human): S129‑p, Akt1 iso2 (human): S67‑p, Akt1 (mouse): S129‑p, Akt1 (rat): S129‑p, Akt1 (fruit fly): E241‑p, Akt1 (cow): S129‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Disease tissue studied:  breast cancer, pancreatic cancer, pancreatic carcinoma
Relevant cell lines - cell types - tissues:  BT-474 (breast cell), BxPC-3 (pancreatic), HUVEC (endothelial)
Cellular systems studied:  cell lines
Species studied:  human
Upstream Regulation
Potential in vivo enzymes for site: 
Type Enzyme Evidence Notes
KINASE CK2A1 (human) pharmacological inhibitor of upstream enzyme
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
silmitasertib decrease

T308-p - Akt1 (human)
Modsite: kDGAtMKtFCGtPEy SwissProt Entrez-Gene
Orthologous residues
Akt1 (human): T308‑p, Akt1 iso2 (human): T246‑p, Akt1 (mouse): T308‑p, Akt1 (rat): T308‑p, Akt1 (fruit fly): T423‑p, Akt1 (cow): T308‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Disease tissue studied:  breast cancer, pancreatic cancer, pancreatic carcinoma
Relevant cell lines - cell types - tissues:  BT-474 (breast cell), BxPC-3 (pancreatic), HUVEC (endothelial)
Cellular systems studied:  cell lines
Species studied:  human
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
silmitasertib decrease

S473-p - Akt1 (human)
Modsite: RPHFPQFsysAsGtA SwissProt Entrez-Gene
Orthologous residues
Akt1 (human): S473‑p, Akt1 iso2 (human): S411‑p, Akt1 (mouse): S473‑p, Akt1 (rat): S473‑p, Akt1 (fruit fly): S586‑p, Akt1 (cow): S473‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Disease tissue studied:  breast cancer, pancreatic cancer, pancreatic carcinoma
Relevant cell lines - cell types - tissues:  BT-474 (breast cell), BxPC-3 (pancreatic), HUVEC (endothelial)
Cellular systems studied:  cell lines
Species studied:  human
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
silmitasertib decrease

T145-p - p21Cip1 (human)
Modsite: QGRkRRQtsMTDFyH SwissProt Entrez-Gene
Orthologous residues
p21Cip1 (human): T145‑p, p21Cip1 (mouse): T140‑p, p21Cip1 (dog): T113‑p
Characterization
Methods used to characterize site in vivo immunoassay, phospho-antibody, western blotting
Disease tissue studied:  breast cancer, pancreatic cancer, pancreatic carcinoma
Relevant cell lines - cell types - tissues:  BT-474 (breast cell), BxPC-3 (pancreatic), HUVEC (endothelial)
Cellular systems studied:  cell lines
Species studied:  human
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
silmitasertib decrease
Downstream Regulation
Effect of modification (function):  protein degradation
Effect of modification (process):  carcinogenesis, induced, cell cycle regulation

S370-p - PTEN (human)
Modsite: TSVtPDVsDNEPDHy SwissProt Entrez-Gene
Orthologous residues
PTEN (human): S370‑p, PTEN iso2 (human): S543‑p, PTEN (mouse): S370‑p, PTEN (rat): S370‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Disease tissue studied:  breast cancer, pancreatic cancer, pancreatic carcinoma
Relevant cell lines - cell types - tissues:  BT-474 (breast cell), BxPC-3 (pancreatic), HUVEC (endothelial)
Cellular systems studied:  cell lines
Species studied:  human
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
silmitasertib decrease

S380-p - PTEN (human)
Modsite: EPDHyRYsDttDsDP SwissProt Entrez-Gene
Orthologous residues
PTEN (human): S380‑p, PTEN iso2 (human): S553‑p, PTEN (mouse): S380‑p, PTEN (rat): S380‑p
Characterization
Methods used to characterize site in vivo phospho-antibody, western blotting
Disease tissue studied:  breast cancer, pancreatic cancer, pancreatic carcinoma
Relevant cell lines - cell types - tissues:  BT-474 (breast cell), BxPC-3 (pancreatic), HUVEC (endothelial)
Cellular systems studied:  cell lines
Species studied:  human
Upstream Regulation
Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
silmitasertib decrease